Ahmet SARICI, Mehmet Ali ERKURT, İrfan KUKU, Emin KAYA, İlhami BERBER, Soykan BİÇİM, Emine HİDAYET, Ahmet KAYA, Aşkı VURAL, Onur Selçuk YİĞİT, Mehmet Fatih UZANULU, Musa AK
Journal of Current Hematology & Oncology Research - 2026;4(2):47-52
Aims : Lymphomas are heterogeneous hematologic malignancies for which autologous hematopoietic stem cell transplantation (ASCT) remains an important therapeutic option in relapsed or refractory disease. In addition to patient- and disease-related factors, graft-related parameters-particularly the infused CD34 ? cell dose-play a critical role in hematopoietic recovery after ASCT. This study aimed to evaluate post-transplant engraftment and long-term survival outcomes in patients with Hodgkin and non-Hodgkin lymphoma according to infused CD34 ? cell dose. Methods : Demographic characteristics, primary diagnosis, infused CD34 ? cell dose, neutrophil and platelet engraftment times, 1-year mortality, and 5-year survival were retrospectively obtained from hospital electronic records. Patients were stratified into two groups based on infused CD34 ? cell dose: 2-5x10?/kg and >5x10?/kg. Engraftment times and survival outcomes were compared between groups. Results : A total of 165 patients were included (2-5x10?/kg, n=67; >5x10?/kg, n=98). Baseline characteristics, including age, sex, and lymphoma subtype, were comparable between groups. Neutrophil and platelet engraftment times were significantly longer in the 2-5x10?/kg group than in the >5x10?/kg group (p<0.001 for both). In the overall cohort, CD34 ? cell dose was negatively correlated with engraftment times. However, no significant differences were observed in 1-year mortality or 5-year survival between groups. Conclusion : Adequate CD34 ? cell dosing is essential for rapid hematopoietic recovery after ASCT, whereas higher doses do not appear to confer additional long-term survival benefit.
